Idarubicin
Top View
- A Phase I Trial of a Single High Dose of Idarubicin Combined With
- Dose-Finding and Pharmacologic Study of Chronic Oral Idarubicin Therapy in Metastatic Breast Cancer Patients1
- ©Ferrata Storti Foundation
- Policy for the Management of Extravasation
- Venetoclax-Based Therapies for Acute Myeloid Leukemia T ∗ Veronica A
- Mitoxantrone | Memorial Sloan Kettering Cancer Center
- Treating Chronic Myelomonocytic Leukemia If You’Ve Been Diagnosed with Chronic Myelomonocytic Leukemia (CMML), Your Treatment Team Will Discuss Your Options with You
- Chemotherapy in Patients with Prostate Specific Antigen–Only
- How to Order Chemotherapy at Shands at the University of Florida - Inpatient
- Chemogenomic Screening Identifies the Hsp70 Co-Chaperone HDJ2 As
- Idarubicin to Intensify the Conditioning Regimens of Autologous Bone Marrow Transplantation for Patients with Acute Myeloid Leukemia in first Complete Remission
- Management of Extravasation of a Systemic Anti-Cancer Therapy Including Cytotoxic Agents
- Combining CDK2/9 Inhibitor CYC065 with Venetoclax, a BCL2 Inhibitor, to Treat Patients with Relapsed Or Refractory AML Or MDS
- Idarubicin Hydrochloride for Injection, USP
- Clinical Policy: Venetoclax (Venclexta)
- Idamycin® Idarubicin Hydrochloride for Injection, USP
- Randomized Trial of Intermediate-Dose Cytarabine In
- Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed Or Relapsed/Refractory AML